FDA Orange Book · active-ingredient family
Avobenzone; ecamsule; octocrylene; titanium dioxide
Avobenzone; ecamsule; octocrylene; titanium dioxide is approved in 2 FDA applications, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:ANTHELIOS 40 · NDA 022009
2
Brand (NDA)
0
Generics (ANDA)
0
Listed patents
0
Exclusivity periods
Brand (NDA) products · cream
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| ANTHELIOS 40RLD×2 | LOREAL USA | NDA 022009 | — | Mar 31, 2008 | |
| ANTHELIOS 20RLD | LOREAL USA | NDA 021471 | — | Oct 05, 2006 |
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Avobenzone; ecamsule; octocrylene; titanium dioxide — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
